“Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study”, J Patan Acad Health Sci, vol. 5, no. 1, pp. 47–56, Jun. 2018, doi: 10.3126/jpahs.v5i1.24042.